Fig. 2

Hypoxia-driven proliferation can be inhibited in MDA-MB-231 but not MCF7. Cell proliferation was measured by BrdU incorporation in (A-C) MDA-MB-231and (D-F) MCF7 cells treated with subtype-specific NPYR antagonists (Y1^- or Y5^-) following stimulation in normoxia and hypoxia. A general agonist that stimulates all NPYR subtypes (NPY) or subtype-specific agonists (Y1⁺ or Y5⁺) were used. Data (n ≥ 3) represent the mean % BrdU-positive cells after treatment relative to vehicle control. The Bartlett test was used to verify that all data sets were normally distributed. Bar graph with error bars representing the SEM and * represent p < 0.05 using a one-way ANOVA and Tukey’s HSD post-hoc test